Probiotic Efficacy Evaluation Service in Chronic Inflammatory Models

We can evaluate single-strain candidates, multi-strain blends, spore-forming probiotics, formulated products, and novel live biotherapeutic candidates. Intake review covers identity, concentration, formulation, excipients, storage, handling, and available viability or stability information so dosing procedures reflect the actual product.

Yes. We can help compare available strain information, functional data, formulation constraints, target mechanism, and intended disease context. Where useful, an initial screening or pilot study can reduce the number of candidates entering a longer chronic model.

Yes. Client-supplied diets or vehicles can be considered during feasibility review. We assess compatibility with the model, dosing route, animal intake, candidate viability, storage, and control groups before the final protocol is set.

Preventive dosing begins before or with disease induction and asks whether the candidate limits onset or severity. Therapeutic dosing begins after inflammation is established and asks whether the candidate improves active disease. Parallel arms can compare both windows when the program needs a clearer intended-use decision.

Yes. Washout, maintenance, and repeated-challenge phases can be incorporated when supported by the model. Longitudinal scoring and scheduled biospecimens help determine whether efficacy persists, wanes, or changes during recurrence.

The final report includes the study design, materials and methods, quality observations, detailed results, statistical outputs, figures and tables, pathology documentation where applicable, conclusions, limitations, and an integrated interpretation. Associated raw and processed data files are organized for internal review and future comparison.